HRP20140744T1 - Uporaba amisulprida za lijeäśenje post-operativne muäśnine i povraä†anja - Google Patents

Uporaba amisulprida za lijeäśenje post-operativne muäśnine i povraä†anja Download PDF

Info

Publication number
HRP20140744T1
HRP20140744T1 HRP20140744AT HRP20140744T HRP20140744T1 HR P20140744 T1 HRP20140744 T1 HR P20140744T1 HR P20140744A T HRP20140744A T HR P20140744AT HR P20140744 T HRP20140744 T HR P20140744T HR P20140744 T1 HRP20140744 T1 HR P20140744T1
Authority
HR
Croatia
Prior art keywords
amisulpride
use according
vomiting
patient
operative nausea
Prior art date
Application number
HRP20140744AT
Other languages
English (en)
Croatian (hr)
Inventor
Julian Clive Gilbert
Robert William Gristwood
Nicola Cooper
Gabriel Fox
Original Assignee
Acacia Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42136792&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20140744(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acacia Pharma Limited filed Critical Acacia Pharma Limited
Publication of HRP20140744T1 publication Critical patent/HRP20140744T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HRP20140744AT 2010-03-11 2011-03-10 Uporaba amisulprida za lijeäśenje post-operativne muäśnine i povraä†anja HRP20140744T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1004020.2A GB201004020D0 (en) 2010-03-11 2010-03-11 New therapeutic use
PCT/GB2011/050472 WO2011110854A2 (en) 2010-03-11 2011-03-10 The use of amisulpride as an anti-emetic

Publications (1)

Publication Number Publication Date
HRP20140744T1 true HRP20140744T1 (hr) 2014-09-26

Family

ID=42136792

Family Applications (3)

Application Number Title Priority Date Filing Date
HRP20140744AT HRP20140744T1 (hr) 2010-03-11 2011-03-10 Uporaba amisulprida za lijeäśenje post-operativne muäśnine i povraä†anja
HRP20140745AT HRP20140745T1 (hr) 2010-03-11 2014-08-01 Uporaba amisulprida za lijeäśenje kemoterapijom izazvane muäśnine i povraä†anja
HRP20180436TT HRP20180436T1 (hr) 2010-03-11 2018-03-14 Upotreba amisulprida u liječenju mučnine i povraćanja uzrokovanih opijatima

Family Applications After (2)

Application Number Title Priority Date Filing Date
HRP20140745AT HRP20140745T1 (hr) 2010-03-11 2014-08-01 Uporaba amisulprida za lijeäśenje kemoterapijom izazvane muäśnine i povraä†anja
HRP20180436TT HRP20180436T1 (hr) 2010-03-11 2018-03-14 Upotreba amisulprida u liječenju mučnine i povraćanja uzrokovanih opijatima

Country Status (26)

Country Link
US (12) US8686019B2 (enExample)
EP (3) EP2544657B1 (enExample)
JP (2) JP5886213B2 (enExample)
KR (1) KR101738201B1 (enExample)
CN (1) CN102892407B (enExample)
AU (1) AU2011225898B2 (enExample)
BR (1) BR112012022746B1 (enExample)
CA (1) CA2792392C (enExample)
CY (3) CY1115485T1 (enExample)
DK (3) DK2567690T3 (enExample)
EA (1) EA030335B1 (enExample)
ES (3) ES2496092T3 (enExample)
GB (1) GB201004020D0 (enExample)
HR (3) HRP20140744T1 (enExample)
HU (1) HUE037088T2 (enExample)
IL (1) IL221746A (enExample)
LT (1) LT2796171T (enExample)
MX (3) MX2012010411A (enExample)
NO (1) NO2796171T3 (enExample)
NZ (1) NZ602279A (enExample)
PL (3) PL2796171T3 (enExample)
PT (3) PT2567690E (enExample)
RS (3) RS57032B1 (enExample)
SI (3) SI2796171T1 (enExample)
SM (3) SMT201800188T1 (enExample)
WO (1) WO2011110854A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201004020D0 (en) 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use
CN104435861A (zh) * 2014-12-22 2015-03-25 济南伟传信息技术有限公司 一种治疗妊娠剧吐的茶
GB201506116D0 (en) * 2015-04-10 2015-05-27 Acacia Pharma Ltd Kit and combination therapy for nausea and vomiting
JP2018530744A (ja) 2015-09-02 2018-10-18 カリフォルニア インスティチュート オブ テクノロジー 低濃度の硫化水素ガスの分光学的検出のための方法および装置
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) * 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
JP2021505595A (ja) 2017-12-05 2021-02-18 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 結晶形およびその製造方法
WO2019113079A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
EP3980009A4 (en) 2019-06-04 2023-07-05 Sunovion Pharmaceuticals Inc. MODIFIED RELEASE FORMULATIONS AND THEIR USE
US20220323409A1 (en) * 2019-06-04 2022-10-13 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
EP4175631A1 (en) 2020-07-06 2023-05-10 Acacia Pharma Ltd Therapy of post-operative nausea and vomiting
WO2023179542A1 (en) 2022-03-21 2023-09-28 Gasherbrum Bio , Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
WO2023198140A1 (en) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN121002014A (zh) 2022-12-15 2025-11-21 加舒布鲁姆生物公司 具有glp-1激动剂活性的化合物的盐和固体形式
CN120693338A (zh) 2022-12-22 2025-09-23 加舒布鲁姆生物公司 杂环的glp-1激动剂
CN120712261A (zh) 2022-12-22 2025-09-26 加舒布鲁姆生物公司 杂环的glp-1激动剂
KR20250168210A (ko) 2023-02-16 2025-12-02 가셔브룸 바이오, 인크. 헤테로시클릭 glp-1 효능제
AU2024311208A1 (en) 2023-06-30 2026-01-15 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
AR133240A1 (es) 2023-07-13 2025-09-10 Aconcagua Bio Inc Compuestos, composiciones y métodos
WO2025015269A1 (en) 2023-07-13 2025-01-16 Aconcagua Bio, Inc. Compounds, compositions, and methods
WO2025045208A1 (en) 2023-08-31 2025-03-06 Gasherbrum Bio, Inc. Heteroaryl-heterocycloalkyl-based glp-1 agonists
WO2025137307A1 (en) 2023-12-20 2025-06-26 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2025171341A2 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity
WO2025171340A1 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. The treatment of calcitonin- and/or amylin-receptor associated conditions
WO2025189141A1 (en) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Methods for treating obesity and increasing weight loss

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2415099A1 (fr) * 1978-01-20 1979-08-17 Ile De France Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
US6169094B1 (en) * 1998-07-14 2001-01-02 Sanofi-Synthelabo Compositions of (S) (-)-amisulpride
DE10163421A1 (de) * 2001-12-21 2003-07-31 Gruenenthal Gmbh Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
DE102005013726A1 (de) * 2005-03-22 2006-09-28 Grünenthal GmbH Transdermale therapeutische Systeme mit verbesserter Verträglichkeit
GB0506800D0 (en) * 2005-04-04 2005-05-11 Merck Sharp & Dohme New uses
US8551986B2 (en) * 2005-12-08 2013-10-08 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
ES2531215T3 (es) 2006-01-27 2015-03-11 Aptalis Pharmatech Inc Sistemas de administración de fármacos que comprenden un agente de bloqueo selectivo de la serotonina 5-HT3 débilmente básico y ácidos orgánicos
EP1988883A1 (fr) * 2006-02-17 2008-11-12 Trimaran Limited Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions
US7825156B2 (en) * 2007-02-02 2010-11-02 Copharms Method of treating bipolar depression with a benzamide derivative
ES2620672T3 (es) * 2008-01-09 2017-06-29 Charleston Laboratories, Inc. Comprimidos de doble capa que comprenden oxicodona y prometazina
WO2009126931A2 (en) * 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
GB201004020D0 (en) 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use

Also Published As

Publication number Publication date
JP5886213B2 (ja) 2016-03-16
US20200093792A1 (en) 2020-03-26
US9545426B2 (en) 2017-01-17
US20210228543A1 (en) 2021-07-29
MX370629B (es) 2019-12-18
KR20130045241A (ko) 2013-05-03
HRP20180436T1 (hr) 2018-05-04
PT2796171T (pt) 2018-04-24
EP2544657B1 (en) 2014-07-16
SMT201400127B (it) 2015-05-05
PL2567690T3 (pl) 2014-11-28
CY1115487T1 (el) 2017-01-04
PT2567690E (pt) 2014-09-03
US20150335616A1 (en) 2015-11-26
RS53467B (sr) 2014-12-31
CA2792392A1 (en) 2011-09-15
EP2796171B1 (en) 2018-01-31
US9084765B2 (en) 2015-07-21
EP2567690B1 (en) 2014-07-16
SMT201800188T1 (it) 2018-07-17
US10085970B2 (en) 2018-10-02
LT2796171T (lt) 2018-05-10
MX2012010411A (es) 2012-11-30
CN102892407B (zh) 2016-03-23
DK2796171T3 (en) 2018-05-07
AU2011225898A1 (en) 2012-10-04
SI2567690T1 (sl) 2014-12-31
RS57032B1 (sr) 2018-05-31
MX2019015396A (es) 2020-02-07
US9119836B2 (en) 2015-09-01
SI2796171T1 (en) 2018-05-31
HUE037088T2 (hu) 2018-08-28
JP2013522181A (ja) 2013-06-13
EP2567690A1 (en) 2013-03-13
EA201290833A1 (ru) 2013-09-30
WO2011110854A3 (en) 2011-11-10
US20180353473A1 (en) 2018-12-13
US20250186394A1 (en) 2025-06-12
CY1115485T1 (el) 2017-01-04
SI2544657T1 (sl) 2014-12-31
GB201004020D0 (en) 2010-04-21
EP2544657A2 (en) 2013-01-16
CN102892407A (zh) 2013-01-23
HK1179152A1 (zh) 2013-09-27
RS53466B (sr) 2014-12-31
DK2544657T3 (da) 2014-08-11
US10525033B2 (en) 2020-01-07
US20220296570A1 (en) 2022-09-22
US20180042896A1 (en) 2018-02-15
US20130022689A1 (en) 2013-01-24
US20170087128A1 (en) 2017-03-30
SMT201400126B (it) 2015-05-05
CA2792392C (en) 2018-06-19
DK2567690T3 (da) 2014-08-11
BR112012022746A2 (pt) 2016-07-05
US20130022688A1 (en) 2013-01-24
US20140147517A1 (en) 2014-05-29
WO2011110854A2 (en) 2011-09-15
US8686019B2 (en) 2014-04-01
ES2496099T3 (es) 2014-09-18
PL2544657T3 (pl) 2014-10-31
ES2665418T3 (es) 2018-04-25
NZ602279A (en) 2014-08-29
AU2011225898B2 (en) 2014-07-03
MX388787B (es) 2025-03-20
KR101738201B1 (ko) 2017-05-19
EP2796171A1 (en) 2014-10-29
HRP20140745T1 (hr) 2014-09-26
US12194022B2 (en) 2025-01-14
BR112012022746B1 (pt) 2021-09-28
US20230144973A1 (en) 2023-05-11
IL221746A (en) 2017-03-30
US9889118B2 (en) 2018-02-13
EA030335B1 (ru) 2018-07-31
NO2796171T3 (enExample) 2018-06-30
PL2796171T3 (pl) 2018-07-31
CY1120170T1 (el) 2018-12-12
PT2544657E (pt) 2014-09-03
JP6279526B2 (ja) 2018-02-14
ES2496092T3 (es) 2014-09-18
JP2016028090A (ja) 2016-02-25

Similar Documents

Publication Publication Date Title
HRP20140744T1 (hr) Uporaba amisulprida za lijeäśenje post-operativne muäśnine i povraä†anja
NZ587297A (en) Use of anti-CGRP (calcitonin gene-related peptide) antagonists to treat inflammatory pain
NZ586221A (en) Dosing regimen associated with long acting injectable paliperidone esters
WO2009065406A3 (en) Novel cyclic hydrocarbon compounds for the treatment of diseases
FI3757126T3 (fi) Menetelmä nivelreuman hoitamiseksi il-17-antagonistien avulla
HRP20180237T4 (hr) Metode za liječenje hcv-a
MA32784B1 (fr) Composes aryles substitues par heterocycle comme inhibiteurs de hif
GT201300235A (es) Uso de 2,3-dihidroimidazo (1,2-c) quinazolinas sustituidas
NZ601559A (en) Platelet-derived growth factor compositions and methods for the treatment of tendinopathies
RU2015135843A (ru) Терапевтическое средство от грыжи межпозвоночного диска
NZ576424A (en) Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
EP4606430A3 (en) Use of il-22 dimer in manufacture of a medicament for intravenous administration
MX2009009132A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y naltrexona.
MX2009009133A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y naloxona.
NZ595046A (en) Compositions and methods for extended therapy with aminopyridines
MX2015003035A (es) Administracion de inhibidores de acetilcolinesterasa para mitigar la paralisis inducida por neurotoxinas y el bloqueo neuromuscular residual.
CY1109743T1 (el) Παραγωγα των 2-βενζοϋλο-ιμιδαζοπυριδινων, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη
MX2009009134A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y nalmefeno.
JP2007119497A5 (enExample)
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
TW201129361A (en) Methods for treating pain
NZ604009A (en) A combination composition comprising ibuprofen and paracetamol
WO2007095609A3 (en) Use of benzo-heteroaryl sulfamide derivatives for the treatment of mania and bipolar disorder
WO2012040164A3 (en) Tlr5 ligands, therapeutic methods, and compositions related thereto
MX2010010372A (es) Uso de la composicion morfina-metamizol como medicamento para el tratamiento del dolor neuropatico.